# Safety and Preliminary Anti-Tumor Activity of TYRA-430 in Advanced Hepatocellular Carcinoma and Other Solid Tumors With Activating FGF/FGFR Pathway Aberrations

> **NCT06915753** · PHASE1 · RECRUITING · sponsor: **Tyra Biosciences, Inc** · enrollment: 100 (estimated)

## Conditions studied

- Metastatic Hepatocellular Carcinoma
- Solid Tumors
- Solid Tumor, Adult
- FGFR Gene Amplification
- FGFR Gene Alterations
- FGFR3 Gene Alteration
- FGFR3 Gene Mutation
- Advanced Solid Tumors
- FGFR4 Gene Mutation
- FGFR4 Gene Fusions
- FGF19 Gene Amplification
- FGF19 Gene Overexpression
- FGFR3 Gene Fusions
- Locally Advanced Unresectable Hepatocellular Carcinoma

## Interventions

- **DRUG:** TYRA-430

## Key facts

- **NCT ID:** NCT06915753
- **Lead sponsor:** Tyra Biosciences, Inc
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-04-24
- **Primary completion:** 2028-01
- **Final completion:** 2028-09
- **Target enrollment:** 100 (ESTIMATED)
- **Last updated:** 2025-11-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06915753

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06915753, "Safety and Preliminary Anti-Tumor Activity of TYRA-430 in Advanced Hepatocellular Carcinoma and Other Solid Tumors With Activating FGF/FGFR Pathway Aberrations". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT06915753. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*